Wanbury Limited, a well-established name in the pharmaceutical space, has launched its latest innovation — Wanbury C RED — a next-gen Liposomal Iron supplement aimed at tackling anemia more effectively.
This new formula combines Ferric Diphosphate (Ferric Pyrophosphate), Vitamin C, Vitamin B12, and Folic Acid to offer better absorption, fewer gastric side effects, and no metallic aftertaste — common issues with traditional iron supplements. Most importantly, it avoids calcium chelation, making it safe for long-term use, particularly for pregnant women and those with chronic iron deficiency.
Wanbury C RED is already receiving positive feedback from healthcare professionals across North and South India. Encouraged by this early success, the company plans to roll out the supplement nationwide in the coming months.
The launch also marks Wanbury’s return to the iron supplement segment after divesting its earlier blockbuster brand C Pink to Cipla. With C RED, Wanbury aims to reclaim leadership in the gynecology and anemia therapy space.
With anemia still affecting over 40% of India’s population, Wanbury’s timely innovation could play a vital role in improving public health outcomes.
